Efficacy of canakinumab in patients with Still’s disease across different lines of biologic therapy: real-life data from the International AIDA Network Registry for Still’s Disease

IntroductionThe effectiveness of canakinumab may change according to the different times it is used after Still’s disease onset. This study aimed to investigate whether canakinumab (CAN) shows differences in short- and long-term therapeutic outcomes, according to its use as different lines of biolog...

Full description

Bibliographic Details
Main Authors: Antonio Vitale, Valeria Caggiano, Petros P. Sfikakis, Lorenzo Dagna, Giuseppe Lopalco, Gaafar Ragab, Francesco La Torre, Ibrahim A. Almaghlouth, Maria Cristina Maggio, Jurgen Sota, Abdurrahman Tufan, Andrea Hinojosa-Azaola, Florenzo Iannone, Roberta Loconte, Katerina Laskari, Haner Direskeneli, Piero Ruscitti, Maria Morrone, Henrique A. Mayrink Giardini, Alexandros Panagiotopoulos, Ilenia Di Cola, Eduardo Martín-Nares, Sara Monti, Ludovico De Stefano, Rıza Can Kardas, Rahime Duran, Corrado Campochiaro, Alessandro Tomelleri, Abdulaziz Mohammed Alabdulkareem, Carla Gaggiano, Maria Tarsia, Elena Bartoloni, Mery Romeo, Mohamed A. Hussein, Ahmed Hatem Laymouna, Isabele Parente de Brito Antonelli, Marilia Ambiel Dagostin, Lampros Fotis, Sara Bindoli, Luca Navarini, Fatma Alibaz-Oner, Gizem Sevik, Micol Frassi, Francesco Ciccia, Daniela Iacono, Francesca Crisafulli, Piero Portincasa, Nour Jaber, Perla Ayumi Kawakami-Campos, Ewa Wiesik-Szewczyk, Annamaria Iagnocco, Gabriele Simonini, Paolo Sfriso, Alberto Balistreri, Roberto Giacomelli, Giovanni Conti, Bruno Frediani, Claudia Fabiani, Luca Cantarini
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-12-01
Series:Frontiers in Medicine
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2023.1256243/full